Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EFFECT-neo: Pembrolizumab + Chemotherapy in Neoadjuvant LA HNSCC
NCT06102395Phase 3Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- May 2023
- Primary completion
- Apr 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Beijing Tongren Hospital. Primary endpoint: Pathological complete response rate at 12 weeks. Started May 2023; status: recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06102395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06102395.